Clinical Trials Logo

Filter by:
NCT ID: NCT06139250 Not yet recruiting - Clinical trials for Hypoxia-Ischemia, Brain

Development of a High-speed Multimodal Photoacoustic/Ultrasound System for Functional Imaging of the Neonatal Brain

Start date: January 1, 2024
Phase:
Study type: Observational

In today's medical field, there is a growing emphasis on the development of functional and molecular imaging. Therefore, it has significant technical limitations. To address this issue, this project aims to develop a high-speed multimodal photoacoustic/ultrasound functional imaging system that provides both structural and functional information of tissue and organs, thus enhancing the accuracy of early screening and diagnosis of neonatal cranial lesions. This imaging technology is entirely non-invasive and does not involve ionizing radiation or contrast agents. Products using the same technology have already received FDA approval and entered clinical use in the United States. We develop a new generation of multimodal photoacoustic/ultrasound functional imaging equipment to reveal the physiological characteristics and structural details of neonatal cranial lesions, offering advantages and complementary information compared to traditional medical imaging methods.

NCT ID: NCT06139211 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors. The Recommended dose for phase II trial (RP2D) will be determined based on the safety, tolerability, pharmacokinetics and efficacy.

NCT ID: NCT06139081 Recruiting - Hypoxemia Clinical Trials

Oxygen Delivery Methods of Nasal Catheter on the Incidence of Hypoxemia in Patients With Painless Gastroscopy

Start date: September 22, 2023
Phase: N/A
Study type: Interventional

In this study, patients undergoing painless gastroscopy were selected to change the nasal catheter oxygen delivery mode to oral oxygen delivery after endoscope implantation, in order to explore the effect of this oxygen delivery mode on the incidence of hypoxemia during general anesthesia gastroscopy.

NCT ID: NCT06139042 Recruiting - Pancreatic Cancer Clinical Trials

Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers

Start date: November 1, 2023
Phase:
Study type: Observational

LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.

NCT ID: NCT06138496 Recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

NCT ID: NCT06138353 Recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS)

SXN-CVS
Start date: January 24, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Aneurysmal subarachnoid hemorrhage (SAH) is a frequent worldwide cause for stroke with a mortality of around 30%. Worldwide, almost 500 000 patients have aneurysmal SAH annually.An incidence of 2-16 cases of spontaneous SAH per 100 000 person-years was reported in a recent meta-analysis . Surgical treatment of aneurysms is essential in the acute phase of aSAH patients, either by surgical clipping or by endovascular embolization. Although there are many factors that influence the prognosis of patients with aSAH, cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI) are the main factors contributing to the high mortality rate (30-40% within 30 days) and poor long-term functional prognosis of patients after aSAH. Cerebral vasospasm (CVS) is defined as focal or diffuse temporary narrowing of vessel diameter due to contraction of smooth muscle in the arterial wall, which can be detected by digital subtraction angiography (DSA), transcranial ultrasound Doppler (TCD), magnetic resonance (MR), and CT angiography (CTA) or visualised during intraoperative.The prevalence of CVS after aSAH is 67% , with symptomatic patients (symptomatic vasospasm) in 30-40% of them and leading to ischaemic events in 10-45% of patients. It usually begins 3-4 days after bleeding, peaks at 7-10 days and finally resolves at around 14-21 days. There is no effective treatment to prevent cerebral vasospasm events.Shuxuening Injection is a sterilized aqueous solution made by extraction of Ginkgo biloba. The study aims to clarify the clinical study of the efficacy and safety of Shuxuening Injection (10ml/branch) for the prophylactic of cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage.

NCT ID: NCT06138340 Recruiting - Clinical trials for Postoperative Delirium

The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma

Start date: August 31, 2023
Phase:
Study type: Observational

Perioperative anesthesia can affect postoperative cognitive function. In our previous study, intraoperative dexmedetomidine (Dex) infusion reduced the incidence of delirium within the first 5 days after brain tumor. However, the mechanism is still unclear. With the development of neuroimaging, multimodal neuroimaging technology provide a new method to explore the underlying mechanism. Therefore, the purpose of this study is to analyze the alterations of brain network under sedation and anesthesia by different anesthetics in patients with supratentorial glioma and their association with cognition.

NCT ID: NCT06138210 Recruiting - Clinical trials for Acute Ischemic Stroke

The Effect of GD-iExo-003 in Acute Ischemic Stroke

ExoCURE
Start date: May 27, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.

NCT ID: NCT06138028 Recruiting - Clinical trials for Metastatic Esophageal Squamous Cell Carcinoma

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Start date: September 20, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.

NCT ID: NCT06137911 Completed - Healthy Subjects Clinical Trials

Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.

Start date: September 26, 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of JYP0061 in healthy adult subjects. The main questions it aims to answer are: safety and tolerability of JYP0061 in healthy subjects, the pharmacokinetic characteristics after single and multiple doses and the effect of food on the pharmacokinetic characteristics. Participants will be treated with JYP0061 orally and safety and pharmacokinetic evaluations will be conducted according to the protocol.